Troxonium tosylate in drug-induced Parkinsonism: a controlled comparative study.
D000109:Acetylcholine / Q000096:biosynthesis; D000328:Adult; D001565:Benzoates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011759:Pyrrolidines / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D013451:Sulfonic Acids / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use*
D001565:Benzoates; D010276:Parasympatholytics; D010919:Placebos; D011759:Pyrrolidines; D000644:Quaternary Ammonium Compounds; D013451:Sulfonic Acids; D014282:Trihexyphenidyl; D000109:Acetylcholine; D004298:Dopamine